Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Firm

Read MORE

NEW YORK, Oct. 10, 2019 /PRNewswire/ — Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on behalf of Ra Pharma shareholders concerning the proposed merger with UBC SA. Click here to participate in the…

Share:

Author: HEDGE

Executive Editor and Founder of HEDGEaccordingly.com. Hedge Was Founded in January 22, 2008. Learn more about HEDGEaccordingly